homeDrug delivery in diabetes
| CONTENTS: |
| Introductory comment Guy Furness |
| Altea Therapeutics transdermal PassPort™ System: freedom from insulin injections for superior diabetes management Yogi R Patel (Altea Therapeutics) |
| The next generation insulin therapy David Brandt and Anders Boss (Mannkind Corporation) |
| Company Profile: Ypsomed |
| Oral-Lyn needle-free buccal delivery of insulin: a product whose time is now Gerald Bernstein (Generex Biotechnology) |
“Drug delivery in diabetes: making effective treatment tolerable”
This edition is one in a series of sponsored themed publications from ONdrugDelivery Ltd. Each issue will focus on a specific topic within the field of drug delivery, and contain up to eight articles contributed by industry experts.
Full contact information appears alongside each article. Contributing companies would be delight- ed to hear from interested readers directly. ONdrugDelivery would also be very pleased to pass on to authors, or answer as appropriate, any queries you might have in relation to this publication or others in the series.
Forthcoming editions cover: needle-free injection; prefilled syringes; nasal drug delivery; oral modified release; solubilising technologies; delivering injectables; novel biomaterials for drug delivery; safer injections and transdermal delivery, among other topics. To find out more about receiving or participating with any of these issues, please contact ONdrugDelivery Ltd.
Contact:
Guy Furness, Managing Director
T: +44 1273 831 370
E: guy.furness@ondrugdelivery.com
Copyright © 2006 ONdrugDelivery Ltd
